This open-label pilot trial evaluated MDMA-assisted brief cognitive-behavioral conjoint therapy (bCBCT) in 8 U.S. military veterans with PTSD and their intimate partners (N=16 total), using an 8-session protocol with 2 MDMA administration sessions plus dyadic integration sessions incorporating integrative behavioral couples therapy elements.
Veterans showed large pre-post PTSD symptom reductions (Cohen's d = 1.25), generally maintained at follow-up. Both veterans and partners showed large improvements in relationship functioning (d = 1.83 and d = 1.29, respectively), though with moderate rebound at follow-up. No serious adverse events were reported.
- Very small sample (N = 8 veteran-partner dyads), limiting generalizability and statistical power. - Open-label, uncontrolled design with no comparator arm, so placebo or expectancy effects cannot be ruled out. - Single-site study; relational gains showed moderate rebound at follow-up, raising durability questions.
MDMA-assisted bCBCT showed a promising early safety and efficacy signal for both PTSD symptoms and relationship functioning in veteran couples, but the tiny sample and lack of a control group mean this is hypothesis-generating only. Clinicians should await larger, controlled trials before considering this approach outside of a research setting.
